Ampersand 2018 Limited Partnership 4

What Happened

• Ampersand 2018 Limited Partnership (reported as a 10% owner) converted 28,000 shares of Interpace Biosciences' Series C Convertible Preferred Stock into 13,861,386 shares of common stock on January 20, 2026. The conversion is reported at an effective price of $2.02 per share, implying a notional value of $28,000,000. The filing reflects the derivative conversion (acquisition of common stock) and the corresponding disposition of the 28,000 preferred shares (derivative disposal).

Key Details

• Transaction date: January 20, 2026; Filing date: February 4, 2026 (filed 15 days after the transaction).
• Conversion details: 28,000 Series C Preferred → 13,861,386 common shares; conversion price basis $2.02/share; notional value ~$28,000,000.
• Reported as: Conversion of derivative security (Code C) — common shares acquired; preferred shares disposed (derivative).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Notable footnotes:
  • Series C preferred converted using stated value $1,000 per preferred share divided by conversion price $2.02 (see F1–F2).
  • Securities held of record by Ampersand 2018 LP; related general partners AMCLP and AMCLLC may be deemed to have voting/investment power but disclaim beneficial ownership except for any pecuniary interest (F3–F4).
  • Series C preferred had no expiration date (F5).

Context

• This was a conversion of a convertible preferred security into common stock — not an open-market buy or sale. Conversions typically reflect contractual terms of prior financing rather than an active market opinion by the holder.
• Ampersand is an institutional/10% owner entity; the filing includes standard disclaimers that related general partners may be deemed to have control but disclaim beneficial ownership beyond pecuniary interest.